A German multicenter real‐world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma

Abstract Bispecific T‐cell engagers (BTCEs) represent a paradigm shift in the treatment of relapsed/refractory multiple myeloma (RRMM). Talquetamab, a GPRC5DxCD3 BTCE, has shown promising results in the MonumenTAL‐1 trial and was recently approved by the Food and Drug Administration and the European...

Descripción completa

Detalles Bibliográficos

Autores principales:	Jan H. Frenking, Christine Riedhammer, Raphael Teipel, Florian Bassermann, Britta Besemer, Moritz Bewarder, Jan Braune, Annamaria Brioli, Franziska Brunner, Maria Dampmann, Roland Fenk, Deniz N. Gezer, Sarah Goldman‐Mazur, Christine Hanoun, Marion Högner, Cyrus Khandanpour, Katja Kolditz, Igor Kos, Jan Krönke, Miriam Kull, Valentine Landrin, Theo Leitner, Maximilian Merz, Ivana vonMetzler, Christian S. Michel, Carsten Müller‐Tidow, Sebastian Theurich, Karolin Trautmann‐Grill, Ralph Wäsch, Romans Zukovs, Mathias Hänel, Leo Rasche, Marc S. Raab
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Wiley 2025-04-01
Colección:	HemaSphere
Acceso en línea:	https://doi.org/10.1002/hem3.70114
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!